✦ LIBER ✦

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

✍ Scribed by Cahn, Pedro; Pozniak, Anton L; Mingrone, Horacio; Shuldyakov, Andrey; Brites, Carlos; Andrade-Villanueva, Jaime F; Richmond, Gary; Buendia, Carlos Beltran; Fourie, Jan; Ramgopal, Moti; Hagins, Debbie; Felizarta, Franco; Madruga, Jose; Reuter, Tania; Newman, Tamara; Small, Catherine B; Lombaard, John; Grinsztejn, Beatriz; Dorey, David; Underwood, Mark; Griffith, Sandy; Min, Sherene

Book ID: 120809637
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 343 KB
Volume: 382
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(13)61221-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily dolutegravir versus raltegrav

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

✍ Raffi, Francois; Rachlis, Anita; Stellbrink, Hans-Jürgen; Hardy, W David; Torti, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 368 KB

Once-daily dolutegravir versus twice-dai

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

✍ Raffi, François; Jaeger, Hans; Quiros-Roldan, Eugenia; Albrecht, Helmut; Belonos 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 274 KB

Once-daily dolutegravir versus darunavir

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

✍ Clotet, Bonaventura; Feinberg, Judith; van Lunzen, Jan; Khuong-Josses, Marie-Aud 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 328 KB

Ritonavir-boosted darunavir combined wit

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

✍ Raffi, François; Babiker, Abdel G; Richert, Laura; Molina, Jean-Michel; George, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 395 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB